H Plus Yangji Hospital
Seoul, South Korea
NCT Number: NCT07103278
The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers
Looking for future studies?
Notify Me19 year and older
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AD-116 Oral Tablet
AD-1161 Oral Capsule
Time frame: pre-dose (0hour) to 72hours
AUCt of AD-116
Time frame: pre-dose (0hour) to 72hours
Cmax of AD-116
Addpharma Inc.
Industry
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06589154
Benign Prostatic Hyperplasia, Genital Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT05200065
Benign Prostatic Hyperplasia, Genital Diseases
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT07645456
Benign Prostatic Hyperplasia, Genital Diseases
Banhā, Qalyubia Governorate, Egypt
View Trial Details